Optimizing the use of cabotegravir plus rilpivirine long-acting therapy in HIV care : evidence, implementation, and unanswered questions

Cabotegravir plus rilpivirine long-acting (CAB + RPV-LA) injectable therapy marks a major milestone in HIV care, offering an efficacious, well-tolerated alternative to daily oral antiretroviral treatment. This article reviews data from pivotal trials and observational studies of CAB + RPV-LA, addressing emerging questions and highlighting key research priorities. We examine factors influencing virological outcomes, including issues related to HIV subtype, archived drug resistance, body mass index, and pharmacokinetics, and discuss challenges related to hepatitis B virus immunity and infection, pregnancy, and adherence. We outline strategies to address barriers to implementation, advocating for a tailored approach to maximize the potential of CAB + RPV-LA in improving outcomes across diverse populations with HIV.

Palavras-chave

HBV long-acting pharmacokinetics resistance subtype

URI

http://hdl.handle.net/10400.26/63144

Citação

Anna Maria Geretti, Marta Boffito, Stefano Bonora, Patrick Braun, Charlotte Charpentier, Federico Garcia, Jade Ghosn, Perpetua Gomes, Anne-Geneviève Marcelin, Thibault Mesplède, Milosz Parczewski, Kyle Ring, Maria Mercedes Santoro, Caroline Solas, Eva Wolf, Chloe Orkin, Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions, Open Forum Infectious Diseases, Volume 12, Issue 7, July 2025, ofaf368, https://doi.org/10.1093/ofid/ofaf368

Editora

Oxford University Press

DOI

10.1093/ofid/ofaf368

Coleções

EM - Artigos Científicos

Licença CC

cclicense-by-nc-nd

Métricas Alternativas

Ver registo completo